Skip to main content

Table 1 Baseline demographic and clinical characteristics

From: Differences in lipid metabolism between anagliptin and sitagliptin in patients with type 2 diabetes on statin therapy: a secondary analysis of the REASON trial

 Overall cohort (N = 353)Randomly extracted cohort (N = 100)
Anagliptin (n = 177)Sitagliptin (n = 176)Anagliptin (n = 50)Sitagliptin (n = 50)
Age, year68 ± 1068 ± 967 ± 868 ± 9
Female67 (38)72 (41)19 (38)18 (36)
Body mass index, kg/m226.5 ± 4.025.9 ± 3.526.1 ± 3.524.7 ± 2.7
Systolic blood pressure, mm Hg134 ± 16132 ± 16130 ± 14134 ± 19
Diastolic blood pressure, mm Hg74 ± 1271 ± 1170 ± 1171 ± 10
Smoker92 (52)103 (59)26 (52)31 (62)
 Current smoker30 (17)24 (14)7 (14)8 (16)
 Past smoker62 (35)79 (45)19 (38)23 (46)
Non-drinker102 (58)102 (58)35 (70)26 (52)
Hypertension137 (77)133 (76)38 (76)36 (72)
Coronary artery disease80 (45)79 (45)23 (46)19 (38)
Stroke26 (15)26 (15)7 (14)5 (10)
Treatment
 Renin–angiotensin–aldosterone system inhibitor107 (60)99 (56)29 (58)27 (54)
 Strong statina142 (80)136 (77)37 (74)39 (78)
 Ezetimibe18 (10)12 (7)6 (12)1 (2)
 Metformin87 (49)84 (48)26 (52)18 (36)
 Sulfonylurea46 (26)37 (21)13 (26)10 (20)
 Thiazolidine25 (14)31 (18)9 (18)10 (20)
 Insulin13 (7)15 (9)4 (8)7 (14)
 Other glucose-lowering drugs27 (15)18 (10)9 (18)5 (10)
  1. Data are expressed as mean ± standard deviation or n (%)
  2. aIndicates atorvastatin, rosuvastatin, and pitavastatin